Serum is regarded as an essential supplement to promote survival and growth of cells during culture. However, the potential risk of transmitting diseases disqualifies the use of serum for clinical cell therapy in most countries. Hence, most clinical cell therapy programs have replaced human serum with human serum albumin, which can result in inferior quality of released cell products. Photochemical treatment of different blood products utilizing Intercept technology has been shown to inactivate a broad variety of pathogens of RNA and DNA origin. The present study assesses the feasibility of using pathogen-inactivated, blood groupcompatible serum for use in human pancreatic islet culture. Isolated human islets were cultured at 37°C for 3-4 days in CMRL 1066 supplemented with 10% of either pathogen-inactivated or nontreated human serum. Islet quality assessment included glucose-stimulated insulin release (perifusion), ADP/ATP ratio, cytokine expression, and posttransplant function in diabetic nude mice. No differences were found between islets cultured in pathogen-inactivated or control serum regarding stimulated insulin release, intracellular insulin content, and ADP/ATP ratio. Whether media was supplemented with treated or nontreated serum, islet expression of IL-6, IL-8, MCP-1, or tissue factor was not affected. The final diabetes-reversal rate of mice receiving islets cultured in pathogen-inactivated or nontreated serum was 78% and 87%, respectively (NS). As reported here, pathogen-inactivated human serum does not affect viability or functional integrity of cultured human islets. The implementation of this technology for RNA-and DNA-based pathogen inactivation should enable reintroduction of human serum for clinical cell therapy.
INTRODUCTION
uses psoralen. Psoralen is comprised of small molecules able to pass through cell membranes and capsids, which subsequently bind to the helical regions of the nucleid From the very beginning of modern cell culture, serum has been regarded as an essential supplement to acid. When UV-A light of 300-400 nm is emitted, psoralen is cross-linked to DNA and RNA either free or provide for survival and growth of cells isolated from different species and tissues (13) . Nevertheless, the po-located in the genome, thus blocking both transcription and replication of viruses, bacteria, and protozoa. The tential risk of transmitting different diseases disqualified the use of serum for clinical cell therapy in most coun-efficiency and safety of this technology has been documented for clinical applications of different blood prod-tries. In spite of the increasing efficiency of pathogen screening protocols, the risk for transfusion-transmitted ucts (22, 35, 56) . Preliminary studies demonstrate the principal suitability of this technology for clinical cell infections still persists and remains a major concern of public health care (55). Therefore, the majority of clini-therapy by culturing human T lymphocytes, mesenchymal stem cells, and isolated pancreatic islets in media cal cell therapy programs have replaced human serum with human serum albumin.
supplemented with pathogen-inactivated human serum (54). There are several pathogen inactivation techniques available to treat blood components; however, combined
The present study was initiated to evaluate the feasibility of pathogen inactivation for culturing isolated hu-techniques are considered to provide the highest safety for patients (53) . The Intercept technology, routinely man islets of Langerhans. Although adult pancreatic islets are composed of different populations of highly applied for pathogen inactivation of platelets and plasma, 776 STÅ HLE ET AL. differentiated cells that do not grow in vitro, the enor-positive islets and nonstained particles (Cellimage, Uppsala, Sweden) (15) . mous metabolic demand of this tissue requires careful handling to maintain viability and integrity of these mi-Islet Culture cro-organs in culture. In accordance with the majority of protocols for clinical islet transplantation, isolated hu-After purification, islets were precultured at 37°C in untreated single transfer packs for platelets (Baxter man islets were cultured for a period of 3-4 days in CMRL 1066. The culture medium was supplemented Medical AB, Stockholm, Sweden) (20) utilizing CMRL 1066 (Mediatech Inc., Manassas, VA, USA) supple-with heat-inactivated human serum that was either untreated or pathogen inactivated by means of the Inter-mented with 10 mM HEPES (Invitrogen AB, Stockholm, Sweden), 10 mM nicotinamide (Swedish Phar-cept technology. macy, Umeå, Sweden), 2 mM L-glutamine (Invitrogen), 50 µg/ml gentamicin (Invitrogen), 0.25 µg/ml fungizone MATERIALS AND METHODS (Invitrogen), 5 mM sodium pyruvate (Swedish Phar-Pathogen Inactivation macy), 20 µg/ml ciprofloxacin (Bayer, Leverkusen, Ger-Whole blood was collected from healthy donors and many), and 10% blood group-compatible human serum. allowed to coagulate. Collected serum was pathogen in-After 24-36 h medium was changed and aliquots of activated utilizing the Intercept technology (Cerus Eu-1200 islet equivalents were transferred into untreated perope BV, Amersfoort, Netherlands) as described for hutri dishes (Sterilin, VWR, Stockholm, Sweden) and susman plasma. Briefly, ABO-matched, freshly collected pended into CMRL 1066 supplemented with 10% of serum from six different healthy blood donors was either control human serum or pathogen-inactivated semixed and split into two equal portions. While one alirum. Subsequent to 3-4 days of culture at 37°C islets quot was left untreated as control serum, the other porwere harvested and quality assessment was performed. tion was treated with the Intercept Processing Set for Plasma. The processing set utilizes a closed system con-Islet Characterization sisting of a series of plastic containers. The serum ali-Stimulated insulin release of 20 equally distributed quot (650 ml) was connected via a sterile connection islets was measured in duplicate during dynamic glucose devise and passed through a container of amotosalen hyperifusion (Brandel, London, UK) in order to calculate drochloride (15 ml, 6 mM) into an illumination conthe stimulation index, which was defined as the ratio tainer and mixed thoroughly. The mixture was then exbetween the areas under the curves that were calculated posed to 3 joule/cm 2 UVA light (320-400 nm) from for the low (1.67 mM) and high (16.7 mM) glucose con-Intercept UVA Illuminator (Cerus). Afterwards, the UVAcentrations (20). In some preparations the low glucose treated serum was transferred through a compound advalues were close to zero, giving a very high stimulation sorption device (CAD) to eliminate amotosalen residues index. Therefore, the maximum stimulation index for and into a storage container. Both, control serum and any islet preparation has been set to 30, as this is more pathogen-inactivated serum were then heat inactivated physiologically realistic. The insulin content in the efflufor 30 min at 56°C. ent, collected in 6-min intervals, was determined by using an enzyme immunoassay specific for human insulin Islet Isolation (Mercodia, Uppsala, Sweden). The intracellular insulin content was measured in homogenized islets and nor-Local ethics committees approved all human studies. Research grade pancreata were procured from 12 brain-malized to the DNA content determined by means of the Quant-it Picogreen assay (Invitrogen). dead multiorgan donors within the Nordic Network for Clinical Islet Transplantation utilizing cold perfusion Homogenized islets were also assessed for expression of inflammatory mediators utilizing a Gyrolab? TM work-with either University of Wisconsin solution (ViaSpan, DuPont Pharmaceuticals Ltd., Herts, UK) or Custadiol station (Gyros AB, Uppsala, Sweden). For each chemokine two monoclonal antibodies had to be loaded into a (Köhler Chemie GmbH, Alsbach, Germany). All pancreata were processed in a central isolation unit located Gyrolab Bioaffy 200 CD micro-laboratory disk to bind and detect tissue factor (TF, capture: TFE, Enzyme Re-in Uppsala, Sweden (49).
Islet isolation and purification was performed as pre-search Laboratories, South Bend, USA; detection: CD 142, BD Pharmingen, Stockholm, Sweden), monocyte viously described utilizing either Liberase HI (Roche, Indianapolis, IN, USA) or collagenase NB1 (Serva, Hei-chemoattractant protein-1 (MCP-1, capture and detection: anti-CCL2/MCP-1 R&D Systems, Minneapolis, delberg, Germany) for pancreas digestion (16) . Subsequent to purification and culture, islet yield and purity MN, USA), interleukin-6 (IL-6, capture: rat anti-human IL-6, BD Pharmingen; detection: anti-human IL-6, R&D were determined in a standardized procedure utilizing a digital analysis system that discriminated dithizone-Systems), or interleukin-8 (IL-8, capture and detection:
anti-CXCL8/IL-8 R&D Systems). An aliquot of 80 islets was used to measure the ADP/ATP ratio utilizing the ApoGlow kit (Cambrex Bio Science, Nottingham, UK). Islet in vivo function was assessed in NMRI nude mice (Scanbur AB, Sollentuna, Sweden) rendered diabetic by a single intravenous injection of 90 µg/g alloxan (Sigma-Aldrich AB, Stockholm, Sweden) 3 days prior to transplantation of an aliquot of 3000 islet equivalents beneath the kidney capsule. Blood samples were taken from the recipients' tail vein every 2-4 days and analyzed utilizing a one-touch glucometer (Bayer, Leverkusen, Germany). Pretransplant, the nonfasting serum glucose levels of all recipients exceeded 400 mg/dl. After transplantation nonfasting serum glucose levels <200 mg/dl were defined as normoglycemic and considered as graft function. Thirty-five days posttransplant 
Statistical Analysis
Statistical analysis was performed utilizing Prism 5.0c (GraphPad, La Jolla, CA, USA). Comparison bein cultured islets as displayed in Figure 2 (range 0.0006-0.018) fmol/µg DNA, NS] ( Fig. 2E) , and IL-8 [0.058 (range 0.0003-1.210) vs. 0.0023 (range RESULTS 0.0002-1.090) fmol/µg DNA, NS] (Fig. 2F) were not Islet Characterization affected by the use of pathogen-inactivated serum to that As shown in Figure 1 , the amount of insulin secreted of control serum. during glucose perifusion was similar in both experi-Diabetic Nude Mice Bioassay mental groups. Also, the incubation in culture medium supplemented with either pathogen-inactivated or con-Potency of cultured islets was assessed after transtrol serum did not influence the dynamics of insulin replantation beneath the kidney capsule of diabetic nude lease. The median stimulation index differed only marmice. In concordance with the findings made for islet in ginally between islets cultured in either pathogenvitro function, reduction of hyperglycemia was similar inactivated 11.05 (range 1.2-30) or untreated serum in islet recipients of either experimental group (Fig. 3 ). 19.1 (range 1.1-30, NS, p = 0.57).
The final cure rate of mice receiving islets cultured in Additionally, no difference was observed regarding pathogen-inactivated or nontreated serum was 7 (78%) the median intracellular insulin content of islets cultured and 8 out of 9 (87)%, respectively (NS by Fisher's exact for 3-4 days in pathogen-inactivated 1.45 (range 0.19test). 10.55 ng/ng DNA) or control serum 1.45 (range 0.22-DISCUSSION 7.96 ng/ng DNA, NS) ( Fig. 2A) .
As depicted in Figure 2B , the median ADP/ATP ratio Pathogen inactivation with the Intercept technology was assessed on human serum used for culture of human was slightly higher in islets cultured in pathogen-inactivated serum 0.016 (range 0.01-0.052) when compared islets of Langerhans in a clinical setting. Human islets isolated for clinical purposes are cul-to standard culture conditions 0.010 (range 0.01-0.30). However, this difference did not reach statistical signifi-tured primarily for logistical reasons. Most clinical islet transplant protocols include a culture period of 2-4 days cance (p = 0.26).
Supplementation with pathogen-inactivated serum to facilitate pretransplant tissue quality assessment and islet anti-inflammatory pretreatment, recipient matching did not influence the expression of different chemokines for transplantation, and induction of immunosuppressive virus in North America and the SARS virus in Asia (12, 44) . protocols (6, 24, 39) . In addition, different experimental studies indicated that in vitro culture reduces islet immu-
The Intercept technology using amotosalen and UVA treatment, already in use in many European coun-nogenicity compared to freshly isolated islets (27, 29, 32) . A period of culture has benefits not only for islet recov-tries (50) , has been reported to be safe in preclinical studies (9) (10) (11) and to be well tolerated in a wide range ery, as it replenishes islet ATP stores depleted during both cold ischemia period and the isolation procedure, of patients (22, 41, 42, 45, 52, 56) . It has even been used to prevent transfusion transmission of Chikungunya virus but also increases posttransplant function of human islets transplanted into diabetic nude mice (2, 5, 23, 26) .
during an epidemic (46) . The Intercept technology has proven its efficacy towards bacteria, viruses, and proto-Supplementation of culture medium with serum seems to be important to preserve the functional and zoan parasites (8, 21, 28, (34) (35) (36) (37) 46, 47, 51) . Implementation of this safe and validated method for pathogen inac-morphological integrity of islets. Serum, if added to a suitable culture medium, prevents fragmentation of cul-tivation using Intercept can provide protection from both known and yet unidentified RNA-and DNA-depen-tured islets and preserves the secretory capacity of βcells of different species during culture (1,25). This ef-dent agents.
In conclusion, the present data suggest that human fect seems to be particularly pronounced if serum of the donor species is used for supplementation in comparison serum treated by Intercept technology can be used for human islet cell culture without affecting viability and to xenogenic serum (4, 18) .
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